Skip to main content
. Author manuscript; available in PMC: 2008 Sep 1.
Published in final edited form as: Eur J Heart Fail. 2007 Aug 16;9(9):917–921. doi: 10.1016/j.ejheart.2007.06.013

Figure 1.

Figure 1

Serial measurements in peak V̇O2, peak O2 pulse, V̇E/V̇CO2, and PetCO2 made at 14 ± 3.2 months and 1.4 ± 0.6 months prior to, and 4 ± 2 months after the start of sildenafil treatment (squares); circles represent control PAH patients treated over a similar time period, but without the addition of sildenafil.

P values are shown for within-group and between group comparisons.